Genomic Mining Limited - Period Ending 2020-03-31

Genomic Mining Limited - Period Ending 2020-03-31


Genomic Mining Limited NI039951 true 2019-04-01 2020-03-31 2020-03-31 The principal activity of the company is dormant company Digita Accounts Production Advanced 6.24.8820.0 Software true Dr Paul Harkin Dr Paul Harkin NI039951 2019-04-01 2020-03-31 NI039951 2020-03-31 NI039951 bus:OrdinaryShareClass1 2020-03-31 NI039951 bus:OrdinaryShareClass2 2020-03-31 NI039951 bus:PreferenceShareClass1 2020-03-31 NI039951 core:RetainedEarningsAccumulatedLosses 2020-03-31 NI039951 core:ShareCapital 2020-03-31 NI039951 core:CurrentFinancialInstruments 2020-03-31 NI039951 core:CurrentFinancialInstruments core:WithinOneYear 2020-03-31 NI039951 bus:FRS102 2019-04-01 2020-03-31 NI039951 bus:AuditExempt-NoAccountantsReport 2019-04-01 2020-03-31 NI039951 bus:FullAccounts 2019-04-01 2020-03-31 NI039951 bus:RegisteredOffice 2019-04-01 2020-03-31 NI039951 bus:Director1 2019-04-01 2020-03-31 NI039951 bus:Director2 2019-04-01 2020-03-31 NI039951 bus:OrdinaryShareClass1 2019-04-01 2020-03-31 NI039951 bus:OrdinaryShareClass2 2019-04-01 2020-03-31 NI039951 bus:PreferenceShareClass1 2019-04-01 2020-03-31 NI039951 bus:PrivateLimitedCompanyLtd 2019-04-01 2020-03-31 NI039951 countries:NorthernIreland 2019-04-01 2020-03-31 NI039951 2018-04-01 2019-03-31 NI039951 2019-03-31 NI039951 bus:OrdinaryShareClass1 2019-03-31 NI039951 bus:OrdinaryShareClass2 2019-03-31 NI039951 bus:PreferenceShareClass1 2019-03-31 NI039951 core:RetainedEarningsAccumulatedLosses 2019-03-31 NI039951 core:ShareCapital 2019-03-31 NI039951 core:CurrentFinancialInstruments 2019-03-31 NI039951 core:CurrentFinancialInstruments core:WithinOneYear 2019-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: NI039951

Genomic Mining Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2020

Duffy & Co. (A&T) Ltd
Chartered Accountants
126 Eglantine Avenue
Belfast
Co Antrim
BT9 6EU

 

Genomic Mining Limited

Profit and Loss Account for the Year Ended 31 March 2020

The company has not traded during the year. During this year, the company received no income and incurred no expenditure and therefore made neither profit nor loss.

 

Genomic Mining Limited

(Registration number: NI039951)
Balance Sheet as at 31 March 2020

Note

2020
£

2019
£

Current assets

 

Debtors

3

4

4

Cash at bank and in hand

 

380

380

 

384

384

Creditors: Amounts falling due within one year

5

(15,774)

(15,774)

Net liabilities

 

(15,390)

(15,390)

Capital and reserves

 

Called up share capital

6

50,504

50,504

Profit and loss account

(65,894)

(65,894)

Total equity

 

(15,390)

(15,390)

For the financial year ending 31 March 2020 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved and authorised by the Board on 18 November 2020 and signed on its behalf by:
 

.........................................

Dr Paul Harkin
Director

 

Genomic Mining Limited

Notes to the Financial Statements for the Year Ended 31 March 2020

1

General information

The company is a private company limited by share capital, incorporated in Northern Ireland.

The address of its registered office is:
126 Eglantine Avenue
Belfast
Co Antrim
BT9 6EU

These financial statements were authorised for issue by the Board on 18 November 2020.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

 

Genomic Mining Limited

Notes to the Financial Statements for the Year Ended 31 March 2020

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Debtors

2020
£

2019
£

Other debtors

4

4

4

4

4

Cash and cash equivalents

2020
£

2019
£

Cash at bank

380

380

5

Creditors

2020
£

2019
£

Due within one year

Trade creditors

4,854

4,854

Accruals

10,920

10,920

15,774

15,774

6

Share capital

Allotted, called up and fully paid shares

 

2020

2019

 

No.

£

No.

£

A Ordinary of £0.10 each

200,040

20,004.00

200,040

20,004.00

B Ordinary of £0.10 each

190,000

19,000.00

190,000

19,000.00

A Convertible cumulative redeemable preference of £1 each

11,500

11,500

11,500

11,500

 

401,540

50,504

401,540

50,504